Based on a preclinical study for regulating cell redifferentiation along with blockade of PDGFRɑ 110, a clinical trial is ongoing with the administration of imatinib as an anti-cancer drug by blocking PDGFRɑ function in patients with advanced thyroid cancer (NCT03469011) (Table 4). This evidence concerns the gene PDGFRB and thyroid cancer.